Bristol-Myers Squibb(BMY) 'Cavanpar', remains confirmed safe after drug transition... The rise of the "game changer" in schizophrenia treatment

Bristol Myers Squibb (BMY) announced the clinical trial results confirming patient safety in the conversion strategy of the schizophrenia treatment drug “Culverin,” suggesting the possibility of a shift in treatment paradigms. Patients switching from existing antipsychotic medications to “Culverin,” regardless of the rate of administration, maintained stable symptoms, and there were no cases of treatment discontinuation due to insufficient efficacy.

Bristol Myers Squibb presented Phase 4 clinical trial data at the International Society for Research on Schizophrenia (SIRS) held in Florence, Italy, from 25th to 29th (local time). This study evaluated the stability, safety, and tolerability of symptoms in 105 adult outpatients with schizophrenia during the transition to “Culverin” monotherapy from existing atypical antipsychotic medications.

The clinical trial lasted 8 weeks and compared two crossover conversion strategies involving tapering existing medications over 2 weeks or 4 weeks. Results showed that the average PANSS (Positive and Negative Syndrome Scale) scores of both groups of patients remained below baseline, indicating a stable treatment effect. Notably, no patients discontinued treatment due to insufficient efficacy.

The trial completion rate was also high. About 86% of patients completed the 8-week treatment, with discontinuation rates of 15.1% in the slow conversion group and 13.5% in the fast conversion group, showing little difference. The average PANSS scores decreased by 4.2 and 3.1 points, respectively, and the CGI-S (Clinical Global Impression-Severity) scores reflecting overall clinical severity showed slight improvements in both groups. The PSP (Personal and Social Performance) scores assessing social function also increased, indicating potential improvements in patients’ daily functioning.

Safety results were also positive. Approximately 49% of patients reported adverse events during treatment, all of which were mild, and no new safety signals were identified. Treatment discontinuations due to adverse events were very limited.

Dr. David Walling, who led the study, commented, “While medication conversion is common in schizophrenia treatment, the data supporting it is quite limited. Patients’ conditions remained stable regardless of the speed of conversion to ‘Culverin,’ which will serve as an important reference standard in clinical practice.”

Dr. Harald Hampel, head of the neuroscience division at Bristol Myers Squibb, also stated: “‘Culverin’ is the first treatment drug with a completely new mechanism of action in decades. Its performance in ensuring patient safety and treatment continuity will provide important evidence for healthcare professionals’ prescribing decisions.”

“Culverin” is a dual-action mechanism treatment drug targeting muscarinic receptors, offering a new treatment pathway distinct from existing dopamine-centered therapies. The market views it as a potential “game changer” in the field of schizophrenia treatment, and the results of this clinical trial are seen as evidence supporting its applicability in real-world prescribing environments.

Comment: With a mechanism of action that differs from existing drugs, “Culverin” has also confirmed its stability in the actual clinical conversion process and is expected to strengthen Bristol Myers Squibb’s position in the schizophrenia treatment market in the future.